IL115245A - Tumor necrosis factor inhibiting pharmaceuticals - Google Patents

Tumor necrosis factor inhibiting pharmaceuticals

Info

Publication number
IL115245A
IL115245A IL11524595A IL11524595A IL115245A IL 115245 A IL115245 A IL 115245A IL 11524595 A IL11524595 A IL 11524595A IL 11524595 A IL11524595 A IL 11524595A IL 115245 A IL115245 A IL 115245A
Authority
IL
Israel
Prior art keywords
alkyl
hydrogen
use according
tnf
compound
Prior art date
Application number
IL11524595A
Other languages
English (en)
Other versions
IL115245A0 (en
Inventor
Esther Shohami
Ruth Gallily
Raphael Mechoulam
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Priority to IL11524595A priority Critical patent/IL115245A/en
Publication of IL115245A0 publication Critical patent/IL115245A0/xx
Priority to DE69636308T priority patent/DE69636308T2/de
Priority to AT96930337T priority patent/ATE331503T1/de
Priority to JP9513269A priority patent/JP2000500737A/ja
Priority to US08/952,660 priority patent/US5932610A/en
Priority to EP96930337A priority patent/EP0876143B1/en
Priority to CA002231764A priority patent/CA2231764A1/en
Priority to PCT/IL1996/000108 priority patent/WO1997011668A2/en
Priority to AU69420/96A priority patent/AU708886B2/en
Priority to US09/318,774 priority patent/US6331560B1/en
Priority to US09/971,821 priority patent/US6545041B2/en
Publication of IL115245A publication Critical patent/IL115245A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11524595A 1995-09-11 1995-09-11 Tumor necrosis factor inhibiting pharmaceuticals IL115245A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL11524595A IL115245A (en) 1995-09-11 1995-09-11 Tumor necrosis factor inhibiting pharmaceuticals
AU69420/96A AU708886B2 (en) 1995-09-11 1996-09-10 Tumor necrosis factor (TNF) inhibiting pharmaceuticals
US08/952,660 US5932610A (en) 1995-09-11 1996-09-10 Tumor necrosis factor α (TNF-α) inhibiting pharmaceuticals
AT96930337T ATE331503T1 (de) 1995-09-11 1996-09-10 Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
JP9513269A JP2000500737A (ja) 1995-09-11 1996-09-10 腫瘍壊死因子α（ＴＮＦ−α）阻害性医薬品
DE69636308T DE69636308T2 (de) 1995-09-11 1996-09-10 Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
EP96930337A EP0876143B1 (en) 1995-09-11 1996-09-10 Tumor necrosis factor alpha (tnf-alpha) inhibiting pharmaceuticals
CA002231764A CA2231764A1 (en) 1995-09-11 1996-09-10 Tumor necrosis factor alpha (tnf-.alpha.) inhibiting pharmaceuticals
PCT/IL1996/000108 WO1997011668A2 (en) 1995-09-11 1996-09-10 TUMOR NECROSIS FACTOR ALPHA (TNF-α) INHIBITING PHARMACEUTICALS
US09/318,774 US6331560B1 (en) 1995-09-11 1999-05-26 Tumor necrosis factor alpha (TNF-α) inhibiting pharmaceuticals
US09/971,821 US6545041B2 (en) 1995-09-11 2001-10-04 Tumor necrosis factor alpha (TNF-α) inhibiting pharmaceuticals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11524595A IL115245A (en) 1995-09-11 1995-09-11 Tumor necrosis factor inhibiting pharmaceuticals

Publications (2)

Publication Number Publication Date
IL115245A0 IL115245A0 (en) 1995-12-31
IL115245A true IL115245A (en) 2002-12-01

Family

ID=11067971

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11524595A IL115245A (en) 1995-09-11 1995-09-11 Tumor necrosis factor inhibiting pharmaceuticals

Country Status (9)

Country Link
US (3) US5932610A (enExample)
EP (1) EP0876143B1 (enExample)
JP (1) JP2000500737A (enExample)
AT (1) ATE331503T1 (enExample)
AU (1) AU708886B2 (enExample)
CA (1) CA2231764A1 (enExample)
DE (1) DE69636308T2 (enExample)
IL (1) IL115245A (enExample)
WO (1) WO1997011668A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
WO1999057106A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
HUP0203437A3 (en) 1999-03-22 2003-07-28 Immugen Pharmaceuticals Inc So Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7119108B1 (en) * 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US6995187B1 (en) 1999-10-18 2006-02-07 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001058469A1 (en) * 2000-02-08 2001-08-16 Wax Martin B Methods for treating glaucoma
US6531128B1 (en) 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
AU5969101A (en) 2000-05-12 2001-11-26 Genzyme Corp Modulators of tnf-alpha signaling
EP1785417A3 (en) * 2000-06-22 2007-08-01 Pharmos Corporation Novel non-psychotropic cannabinoids
CA2411585A1 (en) * 2000-06-22 2001-12-27 Pharmos Corporation Novel non-psychotropic cannabinoids
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
WO2002026728A2 (en) * 2000-09-28 2002-04-04 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
JP2004532185A (ja) * 2001-01-26 2004-10-21 ユニバーシティ オブ コネチカット 新規なカンナビミメティックリガンド
JP2005503998A (ja) 2001-01-29 2005-02-10 ユニバーシティ オブ コネチカット 受容体選択性のカンナビミメティックアミノアルキルインドール
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
US7057076B2 (en) * 2001-07-13 2006-06-06 University Of Connecticut Bicyclic and tricyclic cannabinoids
EP1448557A4 (en) * 2001-10-26 2005-02-02 Univ Connecticut HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS
AU2003214226A1 (en) * 2002-03-18 2003-10-08 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
US20050137251A1 (en) * 2002-03-18 2005-06-23 Aaron Garzon Dexanabinol and dexanabinol analogs regulate inflammation related genes
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes
CA2496097A1 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
JP4928079B2 (ja) * 2002-11-21 2012-05-09 ジェンザイム・コーポレーション 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用
EP1562571B1 (en) * 2002-11-21 2011-08-17 Genzyme Corporation Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection
JP2006509038A (ja) * 2002-12-04 2006-03-16 ファーモス コーポレイション 医薬組成物用の高エナンチオマー純度を有するデキサナビノール
NZ594077A (en) * 2005-09-29 2013-02-22 Albany Molecular Res Inc Process for production of delta-9-tetrahydrocannabinol
WO2009059277A1 (en) * 2007-11-02 2009-05-07 University Of South Florida Synergistic modulation of microglial activation by nicotine and thc
GB0915877D0 (en) 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis
GB201207305D0 (en) 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
WO1994012667A1 (en) * 1992-11-27 1994-06-09 The United States Department Of The Army Inhibitors of arachidonic acid metabolites for preventing neurological damage

Also Published As

Publication number Publication date
US6545041B2 (en) 2003-04-08
ATE331503T1 (de) 2006-07-15
AU708886B2 (en) 1999-08-12
US20020049245A1 (en) 2002-04-25
DE69636308T2 (de) 2007-05-31
WO1997011668A2 (en) 1997-04-03
JP2000500737A (ja) 2000-01-25
CA2231764A1 (en) 1997-04-03
EP0876143A2 (en) 1998-11-11
IL115245A0 (en) 1995-12-31
DE69636308D1 (de) 2006-08-10
US5932610A (en) 1999-08-03
EP0876143B1 (en) 2006-06-28
WO1997011668A3 (en) 1997-05-15
EP0876143A4 (en) 2001-06-27
AU6942096A (en) 1997-04-17
US6331560B1 (en) 2001-12-18

Similar Documents

Publication Publication Date Title
US5932610A (en) Tumor necrosis factor α (TNF-α) inhibiting pharmaceuticals
AU2002225026B2 (en) Essential N-3 fatty acids in cardiac insufficiency and heart failure therapy
US5284867A (en) NMDA-blocking pharmaceutical compositions
US20160193268A1 (en) Andrographis paniculata extract
KR101380140B1 (ko) 트리아세틸-3-히드록실페닐아데노신 및 혈지조절에 대한 용도
KR20010093845A (ko) 피브레이트와 세리바스타틴의 복합제제
JP5607013B2 (ja) ユウリコマロンギフォリアの生理活性フラクション
KR101898358B1 (ko) 신경계 손상을 수반하는 질병을 치료하기 위한 오메가 3 지방산 조성물
US20080161389A1 (en) Method of treating ocular hypertension and intestinal disorders by using dianhydrohexite mononitrate derivatives
AU2003214608A1 (en) Dexanabinol and dexanabinol analogs regulate inflammation related genes
US6608105B2 (en) TNF-α production inhibitor comprising kavalactone as an active ingredient
JPH0768235B2 (ja) Ｎｍｄａ遮断薬剤組成物
US20240269104A1 (en) Method for treating parkinson's disease
KR102873768B1 (ko) 멜리사엽 분획 추출물 및 이를 포함하는 신규 약학적 조성물
JPH03271226A (ja) 腎炎治療剤
De Kozak et al. Ginkgo biloba extract (EGb 761) and a platelet-activating factor antagonist protect the retina in experimental autoimmune uveoretinitis
EP0310259A2 (en) Eperisone as a hypotensive agent
JP4615849B2 (ja) プロパフェノン含有神経因性疼痛の鎮痛剤
WO1988009675A1 (en) Inhibition of arachidonic acid metabolism
CN120437101A (zh) 一种菖蒲烷型倍半萜在制备治疗自身免疫性脱髓鞘疾病药物中的应用
CN120459084A (zh) 一种c6-c3类衍生物在制备治疗自身免疫性脱髓鞘疾病药物中的应用
JP2001253825A (ja) 帯状疱疹後神経痛用鎮痛剤
WO2001089525A1 (de) Kombination von cerivastatin mit ace inhibitoren und ihre verwendung in arzneimitteln
CA2554045A1 (en) Method for treating erectile dysfunction
JPH07165569A (ja) 脳機能改善剤

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
MM9K Patent not in force due to non-payment of renewal fees